Heidi M. Mansour, Ph.D., R.Ph. The University of Arizona-Tucson, Tucson, AZ. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Heidi M. Mansour, Ph.D., R.Ph. The University of Arizona-Tucson, Tucson, AZ.


Heidi Mansour Pharmtech editorial advisory board (EAB) member

Heidi M. Mansour, Ph.D., R.Ph.
Dr. Mansour is Assistant Professor of Pharmaceutics and Drug Delivery at The University of Arizona-Tucson, College of Pharmacy, Skaggs Center of Pharmaceutical Sciences in Tucson, Arizona.

She has a BS in pharmacy with honors & distinction (School of Pharmacy-1996), a PhD minor in advanced physical & biophysical chemistry (Dept. of Chemistry-1999), and a PhD major in drug delivery/pharmaceutics (School of Pharmacy-2003) from the University of Wisconsin-Madison (U.W.-Madison). She completed postdoctoral fellowships at the U.W.-Madison and at the University of North Carolina-Chapel Hill (UNC-Chapel Hill) in the Division of Molecular Pharmaceutics receiving the 2007 UNC-Chapel Hill Postdoctoral Award for Research Excellence from the Office of the Vice-Chancellor and the 2007 AAPS (American Association of Pharmaceutical Scientists) Postdoctoral Fellow Award in Research Excellence.

Research in the Mansour lab focuses on the fundamental and applied aspects of surface and interfacial chemistry, nanotechnology, and particle engineering technologies in the design and optimization of advanced drug delivery self-assembly systems. These advanced drug delivery self-assembly systems are optimized for targeted drug delivery, nanomedicine, and multifunctional microparticles and nanoparticles in the solid-state as dry powder inhalation aerosols in the targeted treatment and prevention of several pulmonary diseases. In addition to using in vitro studies and in vivo rodent animal models, a systematic Quality-by-Design (QbD) approach in the solid-state is used and includes comprehensive physicochemical characterization, design of experiments (DOEs), in vitro controlled drug release studies, performance modeling, and prediction. Pulmonary diseases with unmet medical needs that are investigated in vitro and in vivo include lung transplantation, lung cancer, infectious diseases, lung inflammatory diseases, and pulmonary fibrotic diseases. Her research program includes translational nanomedicine, as exemplified by several successful collaborations with physician-scientists.

Dr. Mansour is an active long-time member of many professional organizations (please see websites below for details).  She serves on the journal Editorial Advisory Boards of Pharmaceutical Technology North America, Recent Patents on Nanomedicine, Recent Patents on Drug Delivery & Formulation, and the Journal of Pharmaceutical Technology & Drug Research (United Kingdom).  In addition, she is an active member on the NIH/NICHD U.S. Pediatric Formulations Initiative (PFI) New Drug Delivery Systems (NDDS) Aerosols Working Group.  She regularly serves as an expert reviewer for nearly 40 scientific journals and several book publishers including Elsevier, Pharmaceutical Press-The Royal Pharmaceutical Society of Great Britain, Marcel Dekker, Springer, and Wiley-Interscience. Dr. Mansour has published over 50 peer-reviewed scientific journal papers, 8 book chapters, 70 scientific conference abstracts, and is Co-Editor of a new book on nanomedicine drug delivery by Taylor & Francis/CRC Press.  Her research program enjoys funding from federal sources and the pharmaceutical industry.  She leads a multi-disciplinary group of postdoctoral scholars, visiting scholars, visiting professors, graduate students, and physician-scientist M.D./Ph.D. fellows.  

More information can be found on her websites:
Research

Graduate Program

Google Scholar

LinkedIn

Research Gate

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here